Physician profile
John Walker Mcdonald
NPI 1386834281
$3,684.62
in general payments reported to CMS, 2019-2025
30 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $79.95 · 2021: $526 · 2022: $472 · 2023: $732 · 2024: $847 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,134.16 | 2019-2025 | |
| Janssen Biotech, INC. | $383.37 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $360.50 | 2021-2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $309.63 | 2021-2024 | |
| Pfizer INC. | $237.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.35 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $170.19 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $98.09 | 2022-2025 | Resolution Clip, Orca, Resolution 360 Clip |
| Apollo Endosurgery US INC | $79.52 | 2019 | |
| Covidien LP | $77.00 | 2019 | |
| Genzyme Corporation | $72.76 | 2024-2025 | |
| Gilead Sciences, INC. | $71.31 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $66.33 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.19 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $63.02 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52.13 | 2022-2023 | Terlivaz |
| Celltrion USA INC. | $40.90 | 2024 | Vegzelma |
| Braintree Laboratories, INC. | $39.26 | 2022-2024 | Sutab, Suflave |
| Allergan, INC. | $30.45 | 2019 | |
| Redhill Biopharma INC. | $21.06 | 2022 | |
| Amgen INC. | $19.70 | 2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $18.69 | 2021 | |
| Daiichi Sankyo INC. | $17.83 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.75 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $16.41 | 2023 | Linzess |
| Cumberland Pharmaceuticals, INC. | $14.48 | 2019 | |
| Qol Medical, LLC | $13.04 | 2022 | |
| Intercept Pharmaceuticals, INC. | $12.37 | 2021 | |
| Merck Sharp & Dohme LLC | $12.05 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$59,349.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.